Power3 Medical Products, Inc (PWRME)
Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease).
The breast generally refers to the front of the chest and medically specifically to the mammary gland. “Your mammogram is suspicious for breast cancer.” “Your biopsy was positive for breast cancer.” These are among the most terrifying words a woman can hear from her doctor. Breast cancer elicits so many fears, including those relating to surgery, death, loss of body image, and loss of sexuality. Managing these fears can be facilitated by information and knowledge so that each woman can make the best decisions concerning her care. Optimally, these issues are best discussed with the patient’s doctor on an individual basis.
Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of product NuroPro�, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual’s proteins to detect the presence of disease, a patient’s disease progression, a patient’s response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.
BC-SeraPro� is a proteomic test for the diagnosis of breast cancer. This test is designed to measure the quantitative expression level of 22 protein biomarkers in the serum that differentiate between breast cancer patients and control subjects. The level of the biomarkers from the patient’s serum sample is compared to the Power3 Medical Products’ patient database. Statistical analysis by linear discriminant function will analyze the biomarker levels of the patient sample and assign a probability score for the diagnosis of the patient sample. Probability score is ranged from 0.0 to 1.0. Results of the BC-SeraPro� test should not be considered a standalone diagnosis nor a guarantee and is intended to be used in conjunction with mammography and other accepted modalities.
For more information about Power3 Medical Products, Inc. please visit http://www.power3medical.com
Majestic Gold Corp. (MJS.V)
Gold is used in many places in the standard desktop or laptop computer. The rapid and accurate transmission of digital information through the computer and from one component to another requires an efficient and reliable conductor. Gold meets these requirements better than any other metal. The importance of high quality and reliable performance justifies the high cost.
Majestic Gold Corp. engages in the exploration and development of mineral properties in China. The company focuses on its gold project located in the prolific gold region of Song Jiagou in eastern Shandong Province. Majestic Gold Corp. is headquartered in Vancouver, Canada.
Edge connectors used to mount microprocessor and memory chips onto the motherboard and the plug-and-socket connectors used to attach cables all contain gold. The gold in these components is generally electroplated onto other metals and alloyed with small amounts of nickel or cobalt to increase durability.
Majestic Gold Corp. is a Vancouver-based; TSX Venture Exchange and Frankfurt Exchange listed gold exploration and development company with a very advanced gold deposit in Shandong province of China. On April 23, 2010, the company released an updated NI 43-101- compliant, indicated and inferred gold resource estimate on its Song Jiagou property.
Majestic Gold Corp. is pleased to provide a progress update on the new mill construction for the company’s flagship Song Jiagou project.
The mill is in the commissioning stage and has begun running ore through the mill in order to access the efficiency of the mill. Majestic expects to run at an initial throughput rate of 3,000 tonnes per day and progressively move upwards towards full capacity of 6,000 tonnes per day once the mill is running at optimal efficiency.
Ore that has been stockpiled at the new mill in order to streamline the commissioning process is currently being processed as part of the commissioning stage. In addition, Majestic is pleased to announce that the tailings dam is fully completed and all tailings lines and water return systems are in place and now in use.
They are excited by the prospect of getting the new mill on line and being in a position to significantly increase production levels. This represents a significant milestone in their transition from exploration to production.
For more information about Majestic Gold Corp. visit its website: http://www.majesticgold.net
Massey Energy Co. (NYSE:MEE) will announced its first quarter 2011 financial results after the market closes on May 2, 2011. A results detailing the quarterly results will be distributed through the wire services and media and will also be available on the Investor Relations page of the Company’s website at http://www.masseyenergyco.com. Members of Massey’s management team will hold a conference call to review the first quarter results on Tuesday, May 3, 2011 at 10:00 a.m. Eastern Time. The public is invited to listen to the conference call as it is broadcast live on the Internet.
Massey Energy Company, through its wholly owned subsidiary, A.T. Massey Coal Company, Inc., produces, processes, and sells bituminous coal primarily in the United States.
Dover Corp. (NYSE:DOV) announced that for the first quarter ended March 31, 2011, revenue was $2.0 billion, an increase of 24% over the prior-year period. The revenue increase was driven by organic revenue growth of 19%, a 4% increase from acquisitions and a 1% favorable impact from foreign exchange. Earnings from continuing operations were $183.3 million or $0.96 diluted earnings per share (”EPS”), compared to $121.5 million or $0.65 EPS from continuing operations in the prior-year period, representing increases of 51% and 48%, respectively. Excluding the impact of tax benefits of $0.04 recognized in the quarter, adjusted diluted EPS from continuing operations was $0.92, an increase of 42% over the prior year. The tax benefits of $0.04 were principally related to the favorable resolution of domestic tax positions.
Dover Corporation and its subsidiaries manufacture industrial products and components, as well as provide related services and consumables in the United States and internationally.
Waters Corp. (NYSE:WAT) reported first quarter 2011 sales of $428 million, an increase of 16%, from sales of $368 million in the first quarter of 2010. In the quarter, foreign currency translation added 2% to sales growth. On a GAAP basis, earnings per diluted share (E.P.S.) for the first quarter were $1.01, compared to $0.79 for the first quarter of 2010. On a non-GAAP basis, including the adjustments in the attached reconciliation, E.P.S. grew 28% to $1.04 from $0.81 in the prior year quarter.
Waters Corporation operates as an analytical instrument manufacturer primarily in the United States, Europe, Japan, and Asia. Waters Corporation was founded in 1958 and is based in Milford, Massachusetts.
No comments:
Post a Comment